A Phase I, Open-Label, Dosage Escalation, Study of Multiple Doses of CAVATAK (CVA21; Coxsackievirus A21) Administered Intratumourally in the Treatment of Squamous Cell Carcinoma of the Head and Neck Bearing ICAM-1 Receptors.

Trial Profile

A Phase I, Open-Label, Dosage Escalation, Study of Multiple Doses of CAVATAK (CVA21; Coxsackievirus A21) Administered Intratumourally in the Treatment of Squamous Cell Carcinoma of the Head and Neck Bearing ICAM-1 Receptors.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs CVA 21 (Primary)
  • Indications Head and neck cancer
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 18 Jan 2012 Status changed from recruiting to discontinued, according to a Viralytics media release.
    • 11 Nov 2011 Recruitment is not progressing as anticipated and Viralytics is re-evaluating the strategic value of this trial.
    • 02 Feb 2011 Planned end date changed from Jun 2010 to Jun 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top